FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230405800> ?p ?o ?g. }

• W4230405800 endingPage "152" @default.
• W4230405800 startingPage "141" @default.
• W4230405800 abstract "Botulinum neurotoxin (BoNT) can be injected to achieve therapeutic benefit across a large range of clinical conditions. To assess the efficacy and safety of BoNT injections for the treatment of certain hypersecretory disorders, including hyperhidrosis, sialorrhea, and chronic rhinorrhea, an expert panel reviewed evidence from the published literature. Data sources included English-language studies identified via MEDLINE, EMBASE, CINAHL, Current Contents, and the Cochrane Central Register of Controlled Trials. Evidence tables generated in the 2008 Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (AAN) review of the use of BoNT for autonomic disorders were also reviewed and updated. The panel evaluated evidence at several levels, supporting BoNT as a class, the serotypes BoNT-A and BoNT-B, as well as the four individual commercially available formulations: abobotulinumtoxinA (A/Abo), onabotulinumtoxinA (A/Ona), incobotulinumtoxinA (A/Inco), and rimabotulinumtoxinB (B/Rima). The panel ultimately made recommendations for each therapeutic indication, based upon the strength of clinical evidence and following the AAN classification scale. For the treatment of axillary hyperhidrosis in a total of 923 patients, the evidence supported a Level A recommendation for BoNT-A, with a Level B recommendation for A/Abo and A/Ona and a Level U recommendation (insufficient data) for A/Inco and B/Rima. Five trials in 82 patients supported the use of BoNT in palmar hyperhidrosis, with a Level B recommendation for BoNT-A and a Level C recommendation for BoNT-B; individual formulations received a Level U rating due to insufficient data. BoNT (and all individual formulations) received a Level U recommendation for the treatment of gustatory sweating. Support for use of BoNT in sialorrhea was derived from eight trials in a total of 222 adults and children. Evidence supported a Level B recommendation for A/Abo, A/Ona, and B/Rima and a Level U recommendation for A/Inco. Evidence supported a Level B recommendation for A/Ona for the treatment of allergic rhinitis, based on two Class II studies in 73 patients. A lack of published studies for A/Abo, A/Inco, or B/Rima supported a Level U recommendation for those formulations. Further clarity on the optimal mode of administration and additional studies using other BoNT formulations are needed to fill current evidence gaps." @default.
• W4230405800 created "2022-05-11" @default.
• W4230405800 creator A5005566965 @default.
• W4230405800 creator A5055816568 @default.
• W4230405800 creator A5068655451 @default.
• W4230405800 creator A5073263620 @default.
• W4230405800 creator A5077085473 @default.
• W4230405800 creator A5082439660 @default.
• W4230405800 creator A5084160223 @default.
• W4230405800 date "2013-06-01" @default.
• W4230405800 modified "2023-09-27" @default.
• W4230405800 title "Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders" @default.
• W4230405800 cites W1969516105 @default.
• W4230405800 cites W1973974516 @default.
• W4230405800 cites W1981945889 @default.
• W4230405800 cites W1984289632 @default.
• W4230405800 cites W1988826107 @default.
• W4230405800 cites W1992456227 @default.
• W4230405800 cites W1999424768 @default.
• W4230405800 cites W2012324845 @default.
• W4230405800 cites W2013579770 @default.
• W4230405800 cites W2015123030 @default.
• W4230405800 cites W2017494419 @default.
• W4230405800 cites W2024485207 @default.
• W4230405800 cites W2026417054 @default.
• W4230405800 cites W2028147765 @default.
• W4230405800 cites W2045746960 @default.
• W4230405800 cites W2050956308 @default.
• W4230405800 cites W2052197301 @default.
• W4230405800 cites W2060816555 @default.
• W4230405800 cites W2066768294 @default.
• W4230405800 cites W2067976357 @default.
• W4230405800 cites W2076753712 @default.
• W4230405800 cites W2078413807 @default.
• W4230405800 cites W2083305874 @default.
• W4230405800 cites W2094416353 @default.
• W4230405800 cites W2101639093 @default.
• W4230405800 cites W2101820599 @default.
• W4230405800 cites W2118560862 @default.
• W4230405800 cites W2130633223 @default.
• W4230405800 cites W2140779855 @default.
• W4230405800 cites W2166956447 @default.
• W4230405800 cites W2315468531 @default.
• W4230405800 cites W4237175844 @default.
• W4230405800 cites W4239045474 @default.
• W4230405800 cites W4241783207 @default.
• W4230405800 cites W4255958927 @default.
• W4230405800 doi "https://doi.org/10.1016/j.toxicon.2012.10.020" @default.
• W4230405800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23178324" @default.
• W4230405800 hasPublicationYear "2013" @default.
• W4230405800 type Work @default.
• W4230405800 citedByCount "69" @default.
• W4230405800 countsByYear W42304058002013 @default.
• W4230405800 countsByYear W42304058002014 @default.
• W4230405800 countsByYear W42304058002015 @default.
• W4230405800 countsByYear W42304058002016 @default.
• W4230405800 countsByYear W42304058002017 @default.
• W4230405800 countsByYear W42304058002018 @default.
• W4230405800 countsByYear W42304058002019 @default.
• W4230405800 countsByYear W42304058002020 @default.
• W4230405800 countsByYear W42304058002021 @default.
• W4230405800 countsByYear W42304058002022 @default.
• W4230405800 countsByYear W42304058002023 @default.
• W4230405800 crossrefType "journal-article" @default.
• W4230405800 hasAuthorship W4230405800A5005566965 @default.
• W4230405800 hasAuthorship W4230405800A5055816568 @default.
• W4230405800 hasAuthorship W4230405800A5068655451 @default.
• W4230405800 hasAuthorship W4230405800A5073263620 @default.
• W4230405800 hasAuthorship W4230405800A5077085473 @default.
• W4230405800 hasAuthorship W4230405800A5082439660 @default.
• W4230405800 hasAuthorship W4230405800A5084160223 @default.
• W4230405800 hasConcept C126322002 @default.
• W4230405800 hasConcept C141071460 @default.
• W4230405800 hasConcept C16005928 @default.
• W4230405800 hasConcept C17744445 @default.
• W4230405800 hasConcept C177713679 @default.
• W4230405800 hasConcept C199539241 @default.
• W4230405800 hasConcept C2777478456 @default.
• W4230405800 hasConcept C2778650131 @default.
• W4230405800 hasConcept C2779473830 @default.
• W4230405800 hasConcept C535046627 @default.
• W4230405800 hasConcept C71924100 @default.
• W4230405800 hasConceptScore W4230405800C126322002 @default.
• W4230405800 hasConceptScore W4230405800C141071460 @default.
• W4230405800 hasConceptScore W4230405800C16005928 @default.
• W4230405800 hasConceptScore W4230405800C17744445 @default.
• W4230405800 hasConceptScore W4230405800C177713679 @default.
• W4230405800 hasConceptScore W4230405800C199539241 @default.
• W4230405800 hasConceptScore W4230405800C2777478456 @default.
• W4230405800 hasConceptScore W4230405800C2778650131 @default.
• W4230405800 hasConceptScore W4230405800C2779473830 @default.
• W4230405800 hasConceptScore W4230405800C535046627 @default.
• W4230405800 hasConceptScore W4230405800C71924100 @default.
• W4230405800 hasLocation W42304058001 @default.
• W4230405800 hasLocation W42304058002 @default.
• W4230405800 hasOpenAccess W4230405800 @default.
• W4230405800 hasPrimaryLocation W42304058001 @default.
• W4230405800 hasRelatedWork W1995688333 @default.

• next